2017-07-12T13:12:49-05:00 2016-12-31 BDO USA LLP 8401 GREENSBORO DRIVE 800 MCLEAN VA 22102 990 2016-01-01 311621592 INTERNATIONAL VACCINE INSTITUTE % SEUNGHWA CHEON INTE 8228722803 snu research park 1 gwanak-ro seoul KS 151-742 PHILIP DRIVER DEP DIR OF FIN & OP 7038930600 2017-07-11 true Jeffrey J Schragg P00234543 7038930600 72.192.208.127 54621820171935000009 2017-07-12 P 02B1B18EFD7ADBEA54A08273E5AF702D2A184C9E 8D2263E1A0E0AD3C946283D6EB0E45EBE88746E7 2016 2021-01-29 14:40:06Z JEROME H KIM SNU RESEARCH PARK 1 GWANAK-RO SEOUL KS 151-742 26061531 false X www.ivi.int X 1997 SEE SCHEDULE O 12 11 0 6 0 21104491 25948268 0 0 35005 49021 12547 59613 21152043 26056902 4455317 6221631 0 0 9053946 10343517 0 0 603605 8319983 8459876 21829246 25025024 -677203 1031878 28657279 23484429 24922927 18538434 3734352 4945995 X SEE SCHEDULE O true false 3207872 1542738 The Cholera Vaccine Initiative (CHOVI) 3 project activities carried out in 2016 under CHOVI grant. Firstly, Euvichol : A bridging study to evaluate the safety and immunogenicity of thimerosal-free Euvichol produced in a 600L fermenter was conducted in 2016. The study started in May 2016, and a total of 442 participants were enrolled in this study. WHO PQ was obtained for 100L Euvichol in December 2015 and for 600L Euvichol without thiomersal in September 2016 respectively. Secondly, Cholvax trial and GMP support for Incepta : Production of 3 lots completed in March 2016. The study was started in May 2016, and enrolled a total of 2,052 participants from May to October 2016. Day 42 safety follow-up was completed in November 2016. Thirdly, Cholera surveillance in Malawi: Cholera surveillance is embarked in April 2016. Series of trainings such as lab trainings, Data Management trainings and etc., are held to build local professionals capacities. The surveillance will continue until April 2018 to have two year data. 2465139 930390 Dengue Vaccine Initiative (DVI) One of major strides made in 2016 under Dengue program is the creation of Global Dengue Prevention and Control Consortium (GADC). In recognition for the need for a comprehensive approach including vaccine and vector control, the Dengue Vaccine Initiative (DVI) hosted by IVI and the Partnership for Dengue Control Foundation (PDC) merged to form GDAC on 31 August 2016. In 2016, DVI continued the activities to pave the way for introduction of dengue vaccine through evidence generation, policy and access, regulatory, and advocacy activities. DVI conducted studies on dengue disease and economic burden through field studies in Thailand, Vietnam, Cambodia, Colombia, Burkina Faso, Gabon, and Kenya; continued surveillance, serological surveys, and cost-of-illness survey in these countries; and started to perform various laboratory tests and analysis. Preliminary results from studies were shared and discussed at the Field Investigators meeting in February 2016. DVI/GDAC convened the Dengue Prevention Board Meetings in Malaysia and Mexico, for the Asia Pacific and American region respectively. The meeting focused on providing specific points of considerations in light of the WHO SAGE recommendations on dengue vaccine introduction released in April 2016. DVI/GDAC also convened a meeting of national regulatory authorities (NRAs) from dengue endemic countries in conjunction with WHOs Developing Country Vaccine Regulators Network (DCVRN) meeting in Brazil in November 2016 and discussed regulatory approvals for dengue vaccines for the initial seven countries as well as the 2nd wave countries. 2622991 757570 TSAP (Typhoid Surveillance in sub-Saharan Africa Program) - TSAP aims to generate data on the burden of typhoid fever and other invasive Salmonella infections in Africa through standardized surveillance and disease burden studies among a network of 10 African countries. The Typhoid Fever Surveillance in Africa Program (TSAP), started in 2010 and developed by the International Vaccine Institute, aims to close the data gap on invasive Salmonella infections between African and Asian countries. Surveillance activities in ten TSAP site were completed in 2014. Preliminary incidence data have been presented at different international conferences. The Bill and Melinda Gates Foundation awarded a follow-up grant at the end 2013. The purpose of this new grant is to: (1) develop and validate a risk and typhoid burden prediction model for sub-Saharan Africa, (2) investigate and define the incidence of typhoid fever in four sites in sub-Saharan Africa selected using the model, and (3) assess water quality at the African sites. Following the completed surveillance in all 13 TSAP sites in 10 countries, the data cleaning and analysis is conducted in 2015. As a result, 15 TSAP papers are published in CID. In March 2016, TSAP Supplement publication was issued for Clinical Infectious Diseases. Severe Typhoid in Africa Program (SETA) pilot study was completed in 3 sites (Ghana, Madagascar, Ethiopia). SETA main surveillance started in 3 sites (Ghana, Madagascar, Burkina Faso). And new sites selected in two new SETA countries (Nigeria, Democratic Republic of Congo). 11713210 2990933 20009212 true true false false false false false false false false true false false false true false true false false true true true false false false false false true false true false false false true false false false false false false false false false false false false false true X 0 0 0 false true KS false false false false false false false false X 12 11 true false false false false true false true true false false false true true true true true true true false X SEUNGHWA CHEON 8228722801 snu research park 1 gwanak-ro gwanak-gu, seoul KS 151-742 Adel AF Mahmoud Chairman / Board of Trustee 1.0 0.0 X 500 0 0 George Bickerstaff Director / Board of Trustee 1.0 0.0 X 1250 0 0 Hanna Nohynek Director / Board of Trustee 1.0 0.0 X 1399 0 0 Lee Kyu Hyung Director / Board of Trustee 1.0 0.0 X 1319 0 0 Joseph Kim Director / Board of Trustee 1.0 0.0 X 1250 0 0 George Siber Director / Board of Trustee 1.0 0.0 X 1342 0 0 Fred Binka Director / Board of Trustee 1.0 0.0 X 796 0 0 Lee Jangkeun Director / Board of Trustee 1.0 0.0 X 0 0 0 Jee Youngmee Director / Board of Trustee 1.0 0.0 X 1388 0 0 Sergey Diorditsa Director / Board of Trustee 1.0 0.0 X 796 0 0 Jerome Kim Director General 1.0 0.0 X X 503711 0 138870 Viveka Persson Director / Board of Trustee 1.0 0.0 X 0 0 0 Phil Driver Deputy Dir. Gen of Fin & OPS 40.0 0.0 X 329139 0 7543 In Kyu Yoon Deputy Director General of Sci 40.0 0.0 X 325329 0 76760 Laura Digilio Deputy Dir. Gen of Dev & Deliv 40.0 0.0 X 274557 0 6804 Julia Lynch Deputy Dir. Gen of Dev & Delvy 40.0 0.0 X 179401 0 42997 Deborah Gene Hong Head of PR & Comm 40.0 0.0 X 188459 0 1510 Viliam Pavliak Head, Vaccine Dev Dept 40.0 0.0 X 236340 0 65998 Jean-Louis Excler Head of Clinical Dev & Reg 40.0 0.0 X 222587 0 5904 Sudeep Kothari Senior Research Scientist 40.0 0.0 X 178807 0 1460 Manki Song Head of Clinical Research Lab 40.0 0.0 X 182545 0 3784 2630915 0 351630 21 false true false The Boston Consulting Group Inc PO box 75200 CHICAGO IL 606755200 CONSULTING 692574 Hey Consulting 11F YOUNGPOONG BLDG41 CHEONGGYECHE KS 03188 CONSULTING 223951 2 35059 5620182 20293027 25948268 0 49021 49021 0 0 0 0 0 0 0 0 0 0 0 0 1156 4629 -3473 -3473 MISCELLANEOUS REVENUE 900099 10071 10071 INSURANCE BENEFIT CLAIMED 900099 53015 53015 63086 26056902 -3473 112107 381446 381446 0 5840185 5840185 0 4533355 2886531 1463650 183174 0 4767708 2506259 2048526 212923 616390 309263 274536 32591 280626 132385 142108 6133 145438 72195 66080 7163 0 66330 28363 37967 40741 809 39932 0 0 0 2012302 1661042 210499 140761 0 319223 258198 53302 7723 899404 866355 32535 514 0 1355813 1355813 1650649 1392088 253663 4898 0 255303 162736 91546 1021 0 0 321993 101068 220925 29728 2875 26853 LAB SUPPLIES 1335174 1101278 233896 TRAINING 62010 55019 6991 REPAIRS AND MAINTENANCE 84660 14684 69976 ALLOCATION OF INDIRECT COSTS 17176 2232295 -2215119 9370 4138 -1472 6704 25025024 20009212 4412207 603605 0 0 26528150 21637741 343578 27359 8171 19126 113417 229190 0 0 204658 98927 0 0 369155 407788 7836117 6776065 1085903 1060052 0 0 0 0 0 0 0 0 4247 4246 28657279 23484429 1843335 2734583 0 0 23079592 15803851 0 0 0 0 0 0 0 0 0 0 0 0 24922927 18538434 X 1022190 2233833 2712162 2712162 0 0 3734352 4945995 28657279 23484429 X 1031878 179765 X false true X true false X 17686547 19680492 23508996 21104491 25948268 107928794 0 0 17686547 19680492 23508996 21104491 25948268 107928794 46952620 60976174 231655 8163 72912 35005 49021 396756 0 89690 13778 28581 15859 63086 210994 108536544 8430 0.56180 0.58309 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 7765464 6705412 1060052 70653 70653 1060052 0 0 26061531 26061531 -4629 -4629 26056902 25029653 4629 4629 25025024 25025024 Part XI, Line 4B: Cost of Goods Sold -4,629 Part XII, Line 2D: Cost of Goods Sold 4,629 true East Asia and the Pacific 1 127 Program Services Program Service 15975927 East Asia and the Pacific Grantmaking 1622773 South Asia Grantmaking 2260182 Sub-Saharan Africa Grantmaking 1493866 Europe (Including Iceland and Greenland) Grantmaking 442506 South America Grantmaking 20858 1 127 1 127 21816112 21816112 East Asia and the Pacific Program service 64919 WIRE East Asia and the Pacific PROGRAM SERVICE 174855 WIRE East Asia and the Pacific PROGRAM SERVICE 18105 WIRE East Asia and the Pacific PROGRAM SERVICE 601780 WIRE East Asia and the Pacific PROGRAM SERVICE 151097 WIRE East Asia and the Pacific PROGRAM SERVICE 120242 WIRE East Asia and the Pacific PROGRAM SERVICE 189243 WIRE East Asia and the Pacific PROGRAM SERVICE 85936 WIRE East Asia and the Pacific PROGRAM SERVICE 89741 WIRE East Asia and the Pacific PROGRAM SERVICE 80690 WIRE East Asia and the Pacific PROGRAM SERVICE 41380 WIRE Europe PROGRAM SERVICE 137864 WIRE Europe PROGRAM SERVICE 189641 WIRE Europe PROGRAM SERVICE 115000 WIRE South America PROGRAM SERVICE 20858 WIRE South Asia PROGRAM SERVICE 169826 WIRE South Asia PROGRAM SERVICE 2059260 WIRE South Asia PROGRAM SERVICE 50000 WIRE South Asia PROGRAM SERVICE 22109 WIRE Sub-Saharan Africa PROGRAM SERVICE 39699 WIRE Sub-Saharan Africa PROGRAM SERVICE 54401 WIRE Sub-Saharan Africa PROGRAM SERVICE 190953 WIRE Sub-Saharan Africa program services 60000 WIRE Sub-Saharan Africa program service 81818 WIRE Sub-Saharan Africa PROGRAM SERVICE 15000 WIRE Sub-Saharan Africa PROGRAM SERVICE 265546 WIRE Sub-Saharan Africa PROGRAM SERVICE 20000 WIRE Sub-Saharan Africa PROGRAM SERVICE 27519 WIRE Sub-Saharan Africa PROGRAM SERVICE 200000 WIRE Sub-Saharan Africa PROGRAM SERVICE 208732 WIRE Sub-Saharan Africa PROGRAM SERVICE 12327 WIRE Sub-Saharan Africa PROGRAM SERVICE 107966 WIRE Sub-Saharan Africa PROGRAM SERVICE 202108 WIRE Sub-Saharan Africa PROGRAM SERVICE 16000 WIRE 34 false false false false false false MONITORING GRANTS OUTSIDE THE US THE IVI IS LOCATED IN SEOUL, KOREA WHERE ALL THE GRANT FUNDS ARE MANAGED AND EXECUTED. THE IVI HAS IN PLACE A VERY DETAILED AND RIGOROUS SYSTEM OF FINANCIAL MONITORING. THIS SYSTEM, WHICH IS EVALUATED BY INTERNAL FINANCE PERSONNEL THROUGHOUT THE YEAR AND AUDITED EXTERNALLY EVERY YEAR, IS USED IN CONJUNCTION WITH CAREFUL PROJECT DEVELOPMENT AND IMPLEMENTATION TO ENSURE ACCOUNTABILITY AND BUDGETARY MANAGEMENT RESPONSIBILITY. FOR SUBGRANTS, THE IVI HAS A BROAD OVERALL SYSTEM OF REVIEWING AND TRACKING THE USE OF GRANTS, AND MORE SPECIFIC DAY-To-DAY REVIEW PROCESSES, WHICH INCLUDE THE FOLLOWING: -REVIEWS OF FINANCIAL AND NARRATIVE REPORTS, AUDIT REPORTS, CORRESPONDENCE AND OTHER DOCUMENTATION PROVIDED BY THE GRANTEES -DIRECT COMMUNICATION WITH GRANTEES THROUGH TELEPHONE AND EMAIL FOR QUESTIONS AND TO CHECK ON PROGRESS OF THE PROJECT -ON-SITE VISITS TO THE FIELD SITES TO REVIEW ONE OR MORE ASPECTS OF THE PROJECTS -MONITORING THROUGH AN EXTERNAL AUDIT. A CERTAIN NUMBER OF SUB-GRANTEES ARE SELECTED FOR THE AUDIT EACH YEAR, WHICH IS DONE TO ENSURE FINANCIAL AND EXPENDITURE COMPLIANCE WITH THE RESEARCH AGREEMENT. true FRED HUTCHINSON CANCER RESEARCH CENTER 1100 FAIRVIEW AVE NORTH SEATTLE WA 98109 237156071 501(C)(3) 17765 PROGRAM SERVICE INC RESEARCH LLC 3201 BEECHLEAF CT STE 600 RALEIGH NC 27604 118113 PROGRAM SERVICE INNOVATIONS FOR GLOBAL HEALTH 3240 HURON PEAK AVE Superior CO 80027 201059464 501(C)(3) 133300 PROGRAM SERVICE THE ALBERT B SABIN VACCINE INSTITUTE 2000 PENN AVE NW WASHINGTON DC 20006 061389829 501(C)(3) 93800 PROGRAM SERVICE UNIVERSITY OF FLORIDA BOARD OF TRUSTEES 123 TIGERT HALL GAINSVILLE FL 32611 590974739 501(C)(3) 18468 PROGRAM SERVICE 4 1 MONITORING USE OF GRANTS THE IVI IS LOCATED IN SEOUL, KOREA WHERE ALL THE GRANT FUNDS ARE MANAGED AND EXECUTED. THE IVI HAS IN PLACE A VERY DETAILED AND RIGOROUS SYSTEM OF FINANCIAL MONITORING. THIS SYSTEM, WHICH IS EVALUATED BY INTERNAL FINANCE PERSONNEL THROUGHOUT THE YEAR AND AUDITED EXTERNALLY EVERY YEAR, IS USED IN CONJUNCTION WITH CAREFUL PROJECT DEVELOPMENT AND IMPLEMENTATION TO ENSURE ACCOUNTABILITY AND BUDGETARY MANAGEMENT RESPONSIBILITY. FOR SUBGRANTS, THE IVI HAS A BROAD OVERALL SYSTEM OF REVIEWING AND TRACKING THE USE OF GRANTS, AND MORE SPECIFIC DAY-To-DAY REVIEW PROCESSES, WHICH INCLUDE THE FOLLOWING: -REVIEWS OF FINANCIAL AND NARRATIVE REPORTS, AUDIT REPORTS, CORRESPONDENCE AND OTHER DOCUMENTATION PROVIDED BY THE GRANTEES -DIRECT COMMUNICATION WITH GRANTEES THROUGH TELEPHONE AND EMAIL FOR QUESTIONS AND TO CHECK ON PROGRESS OF THE PROJECT -ON-SITE VISITS TO THE FIELD SITES TO REVIEW ONE OR MORE ASPECTS OF THE PROJECTS -MONITORING THROUGH AN EXTERNAL AUDIT. A CERTAIN NUMBER OF SUB-GRANTEES ARE SELECTED FOR THE AUDIT EACH YEAR, WHICH IS DONE TO ENSURE FINANCIAL AND EXPENDITURE COMPLIANCE WITH THE RESEARCH AGREEMENT. X X X true true X X X X false false false false false false false false false Jerome Kim Director General 302100 0 0 0 201611 0 127486 0 11384 0 642581 0 0 0 In Kyu Yoon Deputy Director General of Sci 221540 0 0 0 103789 0 71336 0 5424 0 402089 0 0 0 Phil Driver Deputy Dir. Gen of Fin & OPS 239817 0 0 0 89322 0 0 0 7543 0 336682 0 0 0 Laura Digilio Deputy Dir. Gen of Dev & Deliv 203078 0 0 0 71479 0 0 0 6804 0 281361 0 0 0 Julia Lynch Deputy Dir. Gen of Dev & Delvy 111208 0 0 0 68193 0 37392 0 5605 0 222398 0 0 0 Deborah Gene Hong Head of PR & Comm 136560 0 0 0 51899 0 0 0 1510 0 189969 0 0 0 Viliam Pavliak Head, Vaccine Dev Dept 166458 0 0 0 69882 0 53600 0 12398 0 302338 0 0 0 Jean-Louis Excler Head of Clinical Dev & Reg 176225 0 0 0 46362 0 0 0 5904 0 228491 0 0 0 Sudeep Kothari Senior Research Scientist 92868 0 0 0 85939 0 0 0 1460 0 180267 0 0 0 Manki Song Head of Clinical Research Lab 155177 0 0 0 27368 0 1985 0 1799 0 186329 0 0 0 COMPENSATION TRAVEL FOR COMPANION: After 15 months of service, the internationally recruited staff is entitled to home leave travel. This entitlement is an economy round trip between duty station and home base for staff, spouse and dependents under 21. TAX INDEMNIFICATION AND GROSS UP PAYMENTS: IN ORDER TO EQUALIZE THE BENEFITS ACCRUED TO INtERNATIONALLY RECRUITED STAFF, IVI COMPENSATES STAFF WHO ARE OBLIGATED TO PAY TAXES ON IVI DERIVED INCOME TO THEIR HOME COUNTRY. ANY TAX SUBSEQUENTLY LEVIED ON THE AMOUNT OF THE REIMBURSEMENT IS NOT REIMBURSED. IN GENERAL, THIS IS TREATED AS TAXABLE COMPENSATION. HOUSING ALLOWANCE: IVI PROVIDES INTERNATIONALLY RECRUITED STAFF IN KOREA WITH A HOUSING ALLOWANCE UP TO 75% OF A CEILING THAT IS ESTABLISHED AND REVIEWED PERIODICALLY. PERSONAL SERVICES (I.E. driver): IVI PROVIDES THE DIRECTOR GENERAL WITH A DRIVER WHICH is INCLUDED IN HIS/HER EMPLOYMENT CONTRACT PACKAGE APPROVED BY THE BOARD OF TRUSTEES. JEROME KIM EMPLOYEE EDUCATION X 15083 7541 false true true DEBORAH GENE HONG EMPLOYEE HOUSING LOAN X 26714 26714 false true true IN-KYU YOON EMPLOYEE EDUCATION X 6809 3404 false true true IN-KYU YOON HOUSING HOUSING LOAN X 12297 7062 false true true SUDEEP KOTHARI EMPLOYEE EDUCATION X 32153 20026 false true true SUDEEP KOTHARI EMPLOYEE HOUSING LOAN X 27375 27375 false true true VINAY KUMAR GUPTA EMPLOYEE HOUSING LOAN X 3167 3167 false true true SUSHANT SAHASTRABUDD EMPLOYEE EDUCATION X 8491 3250 false true true SUSHANT SAHASTRABUDD EMPLOYEE HOUSING LOAN X 9590 6768 false true true JULIA LYNCH EMPLOYEE EDUCATION X 20425 4503 false true true JULIA LYNCH EMPLOYEE HOUSING LOAN X 12840 -3158 false true true PHIL DRIVER EMPLOYEE HOUSING LOAN X 25746 24934 false true true FLORIAN MARKS EMPLOYEE HOUSING LOAN X 27795 27795 false true true JEAN-LOUIS EXCLER EMPLOYEE HOUSING LOAN X 6750 1119 false true true VILIAM PAVLIAK EMPLOYEE HOUSING LOAN X 16465 16465 false true true AYAN DEY EMPLOYEE HOUSING LOAN X 26353 26353 false true true PAOLA RUSSO EMPLOYEE HOUSING LOAN X 25872 25872 false true true 229190 FORM 990, PART I, LINE 1 IVI'S MISSION IS TO DISCOVER, DEVELOP AND DELIVER SAFE, EFFECTIVE AND AFFORDABLE VACCINES FOR GLOBAL PUBLIC HEALTH. ITS VISION IS DEVELOPING COUNTRIES FREE OF SUFFERING FROM INFECTIOUS DISEASE. FORM 990, PART III, LINE 1 IVI is the only international organization in the world exclusively dedicated to discovering, developing and delivering vaccines for global health. IVI focuses on vaccines against infectious diseases of the most impoverished. We aim to make vaccines available and accessible for vulnerable populations in developing countries. We live in an increasingly globalized world where new and emerging infectious diseases can become global health threats. IVI also focuses on vaccines against infectious diseases of major global health concern. Our research spans the entire vaccine spectrum from discovery and preclinical development in our Seoul-based labs to clinical development at field sites in developing countries to generating scientific evidence on the need for vaccination in countries where vaccines are most needed. Our headquarters in Seoul have state-of-the art lab facilities, animal house, and research teams that include clinical immunology, process development, epidemiology, clinical & regulatory, biostatistics & data management, and policy & economic research. Outside of Seoul, we have a global network of field sites in more than 20 countries in Asia, Africa, and the Americas. We manage field sites in collaboration with regional and in-country partners. We work with local partners to implement translational and field research projects, and we also provide training and technical assistance. FORM 990, PART III, LINE 2 The International Vaccine Institute (IVI) will embark on vaccine research initiatives on Middle East Respiratory Syndrome (MERS), a viral respiratory illness caused by the Middle East Respiratory Syndrome Coronavirus (MERS-CoV). Based on the landscape analysis, GeneOnes MERS-CoV DNA vaccine candidate was selected as the first candidate to support for further clinical development in 2016. LabWare BioBanking system was selected for implementation at IVI based on features including biological sample reception, sample storage, tracking, test assignment, result entry, instrument integration, sample batch management, results handling, data analysis, quality assurance, review and result reporting, and auditing capability. Modifications to the IVI laboratory were completed to comply with BSL-3 requirements. Korean CDC concurred with the need for the project to provide a scientific basis for vaccine stockpile estimates. FORM 990, PART V, LINES 1A AND 2A IVI'S HEADQUARTERS IS BASED IN SEOUL, KOREA. SINCE THE ORGANIZATION IS NOT U.S. BASED, THEY ARE NOT REQUIRED TO FILE W-2'S OR 1099'S. AS OF DECEMBER 31, 2016, THE ORGANIZATION REPORTS 127 EMPLOYEES. FORM 990, PART V, LINE 4 IVI is a foreign organization. It is not required to file Form FinCEN 114 (Report of Foreign Bank and Financial Accounts). FORM 990, PART VI, LINE 2 Adel Mahmoud is a Board member of Inovio Pharmaceuticals where Joseph Kim is a CEO & President at. They are both members of IVI Board of Trustees. FORM 990, PART VI, LINE 7A Director General of the Institute is also a voting member of the Board; thus, he/she can participate in the election of the Board. FORM 990, PART VI, LINE 11B THE FINANCE TEAM PREPARES A FIRST DRAFT OF FORM 990 AND THE RELATED SCHEDULES. HR PROVIDES SPECIFIC INFORMATION ON COMPENSATION AND OTHER TEAMS PROVIDE FUNDRAISING, GOVERNANCE AND MANAGEMENT INFORMATION. THE CFO AND SENIOR FINANCE MANAGER REVIEW ALL OF THE FORMS AND SCHEDULES AND CHECK THEM FOR ACCURACY OF THE FINANCIAL INFORMATION. THE REVIEWED DRAFT IS SENT TO MEMBERS OF THE BOARD OF TRUSTEES (BOT) FINANCE COMMITTEE, WHICH IS COMPOSED OF 5 BOT MEMBERS, PLUS THE BOT CHAIRMAN AND IVI DIRECTOR GENERAL. THE PDF FILE OF THE DRAFT IS SENT TO EACH MEMBER VIA ELECTRONIC MAIL. NORMALLY WE GIVE THEM 2 WEEKS FOR THEIR REVIEW, AND THEIR COMMENTS AND QUESTIONS ARE RECEIVED AND ADDRESSED ACCORDINGLY. FORM 990, PART VI, LINE 12C THE IVI HR PROVIDES A COPY OF THE CONFLICT OF INTEREST POLICY TO ALL DIRECTORS, OFFICERS AND STAFF TO COMPLETE ANNUALLY. NOT ONLY PERSONS WITH ACTUAL OR POTENTIAL CONFLICTS OF INTEREST BUT ALSO PERSONS WHO DO NOT HAVE ANY CONFLICTS OF INTEREST MUST SUBMIT A SIGNED COPY OF THE DISCLOSURE OF ACTUAL OR POTENTIAL CONFLICTS OF INTEREST TO THE IVI BOARD SECRETARIAT OR THE IVI HUMAN RESOURCES UNIT AS APPROPRIATE. THE CONFLICT COORDINATOR (DIRECTOR GENERAL) CREATES A CONFLICT COMMITTEE COMPOSED OF THREE OTHER MEMBERS OF THE IVI STAFF TO REVIEW CONFLICT OF INTEREST ISSUES THAT MAY ARISE. THE CONFLICT COMMITTEE SHALL BE RESPONSIBLE FOR ENSURING THAT RELEVANT CONFLICTS OF INTEREST, AND THE PROCEDURES TAKEN TO ELIMINATE, REDUCE OR MANAGE THOSE CONFLICTS, ARE DISCLOSED AT OR PRIOR TO ANY BOARD OF TRUSTEES MEETING. THE COMMITTEE SHALL KEEP A RECORD OF ALL ACTUAL AND POTENTIAL CONFLICTS OF INTEREST AND REPORT ANNUALLY THEREON TO THE BOARD OF TRUSTEES. IN CASE OF TRUSTEES, IVI BOARD SECRETARIAT PROVIDES A COPY OF THE CONFLICT OF INTEREST POLICY TO THE MEMBERS WHEN THEY FIRST JOIN, ALL MEMBERS MUST SUBMIT A SIGNED COPY OF THE DISCLOSURE OF ACTUAL AND POTENTIAL CONFLICTS OF INTEREST TO IVI. THE MEMBERS SHOULD REPORT THEIR CHANGES OF STATUS TO THE BOARD SECRETARIAT. FORM 990, PART VI, LINES 15A and 15B THE IVI UNDERTAKES A COMPREHENSIVE COMPENSATION STUDY FOR ITS OFFICERS AND KEY EMPLOYEES. A COMPENSATION CONSULTANT CONDUCTS THE STUDY AND LOOKS AT COMPENSATION AMONG COMPARABLE ORGANIZATIONS WITH SIMILAR POSITIONS AND RESPONSIBILITIES IN ORDER TO PROVIDE MARKET DATA TO DETERMINE IVI STAFF MEMBER COMPENSATION. COMPENSATION IS SET BY INDEPENDENT PERSONS, AND CONTEMPORANEOUS DOCUMENTATION OF THE PROCESS IS RETAINED. FORM 990, PART VI, LINE 19 The IVI's governing documents-Establishment Agreement, Headquarters Agreement, Constitution and Amendments to the Constitution are available on IVI's website. The Summary of financial report is included in IVI's Annual report. FORM 990, PART XI, LINE 9 FOREIGN CURRENCY EXCHANGE LOSS 179,765